CARY, N.C., Feb. 08, 2017 -- Arysta LifeScience recently announced that it has entered into a global collaboration with DuPont Crop Protection for the development of new foliar insecticides based on the market-leading product, DuPont™ Rynaxypyr® (chlorantraniliprole). The long-term agreement between the two companies allows Arysta LifeScience to combine Rynaxypyr® insect control in premixes with acetamiprid, thereby creating novel insecticidal formulations that more efficiently and conveniently address needs of growers.
“Through our collaboration with DuPont, we are expanding our development of proprietary foliar insecticides for specialty crop protection,” said Diego Lopez Casanello, president, Arysta LifeScience. “The premix formulations will control a broader spectrum of pests than straight Rynaxypyr® products, which will increase its utility to growers in many countries around the world.”
“Our agreement with Arysta LifeScience increases the value of our investment in Rynaxypyr®, and most importantly, gives growers more tools to effectively manage insects,” said Timothy P. Glenn, president, DuPont Crop Protection.
Combining Rynaxypyr® with acetamiprid offers multiple benefits including:
- Broadening the spectrum of control of Rynaxypyr® with activity on sucking pests such as whiteflies, aphids, certain lepidoptera, and micro-lepidoptera
- Fit with a broad range of crop segments, including both row and specialty crops
- Offering flexible application timing suitable for integrated pest management
- Controlling pests that have become resistant to other products
About Arysta LifeScience
Arysta LifeScience is a global agricultural company specializing in the marketing and distribution of innovative crop protection and life science brands. With more than 200 active ingredients, Arysta LifeScience has a well-integrated biological and chemical portfolio to provide complete solutions to growers. The company’s wide range of offerings includes biosolutions, fungicides, herbicides, insecticides and seed treatments. Arysta LifeScience, which has more than 4,000 employees working in over 100 countries to serve customers worldwide, had 2015 revenues of US$1.8 billion. Arysta LifeScience is owned by Platform Specialty Products (www.platformspecialtyproducts.com), a global innovator of technologically advanced specialty chemical products and provider of technical services. For more information on Arysta LifeScience, visit www.arystalifescience.com.
Media Contact: Carey Dorman Director – Corporate Development Platform Specialty Products Corporation 1-561-406-8465


Italy Fines Apple €98.6 Million Over App Store Dominance
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 



